22nd Century Group makes reduced-nicotine and hemp-derived cigarettes and vaping products, with its legacy business built around very low nicotine tobacco. The bull case rests on the regulatory idea that the FDA could eventually mandate lower nicotine content in combustible cigarettes, which would favour a company already holding patents and product tech in that space. The near-term picture is much harder: revenue fell 40.4% year on year, gross margin is negative at -54.6%, and operating margin is -247.8%, so each dollar of sales is currently costing the business more to produce and sell than it brings in. With a market capitalisation of about $448 million, a return on equity of -105.7% and no earnings to value, the stock is priced on a regulatory option rather than on operations, and the score of 26/100 reflects that. It merits a look only if the deeper work turns up evidence of a funded path to positive gross margin or a firm timeline on the nicotine rule.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:52 CEST | ACCE price target | $0.11 | $0.20 | $0.22 |
| 18 Oct 2026, 00:00 CEST | ACCE price target | $0.20 | $0.34 | $0.34 |
| 15 Oct 2026, 00:00 CEST | ACCE price target | $0.34 | first publication | $0.67 |
Answered from 22nd Century Group Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| XXII 22nd Century Group Inc. Common Stock | $0.20 | - | - | 0.0x | -105.7% | 31 | 23 |
| GNLN Greenlane Holdings Inc. Class A Common Stock | $1.99 | - | - | 0.3x | -535.1% | 31 | 29 |
| NICO.ST Nicoccino Holding AB (publ) | kr 1.48 | - | - | - | -152.0% | 43 | 39 |
| RYM RYTHM Inc. Common Stock | $15.63 | - | - | - | -10.5% | 38 | 34 |
| ISPR Ispire Technology Inc. Common Stock | $1.36 | - | - | - | -428.6% | 13 | 29 |
| HAYPP.ST Haypp Group AB (publ) | kr 168.60 | kr 62 | 170% above | 690.4x | 1.1% | 34 | 49 |
| UVV Universal Corporation Common Stock | $39.67 | $59 | 32% below | 50.2x | 2.3% | 34 | 33 |
Where XXII ranks against its sector peers on each metric.